A fixed-dose combination product containing doxylamine succinate, a first-generation ethanolamine antihistamine, and pyridoxine hydrochloride (Vitamin B6). Doxylamine is a potent H1-receptor antagonist with pronounced sedative and antiemetic properties. Pyridoxine is a water-soluble vitamin that serves as a cofactor in amino acid metabolism and neurotransmitter synthesis. In the Indian context, this combination is primarily indicated for the management of nausea and vomiting in pregnancy (NVP), leveraging the antiemetic effect of doxylamine and the potential supportive role of pyridoxine in reducing nausea. It is considered a first-line therapy for NVP as per many international and national guidelines, though its use in India is widespread and often extends to other causes of nausea.
Adult: For NVP: One tablet (10mg/10mg) at bedtime. If symptoms persist, one tablet in the morning may be added. Maximum: 2 tablets per day (20mg/20mg). For other nausea/insomnia: One tablet at bedtime.
Note: Oral administration. Can be taken with or without food. Taking with food may reduce gastric irritation. For NVP, the bedtime dose is crucial to prevent morning sickness. Tablet should be swallowed whole with a glass of water. Do not crush or chew.
The therapeutic effect in nausea and vomiting is primarily attributed to doxylamine. It acts as a competitive antagonist at histamine H1 receptors in the central nervous system, particularly in the vestibular system and the chemoreceptor trigger zone (CTZ) in the area postrema. This blockade inhibits the stimulation that leads to nausea and vomiting. Its strong central antimuscarinic activity also contributes to its antiemetic and sedative effects. Pyridoxine's role is adjunctive. It is a cofactor in the synthesis of neurotransmitters like GABA, serotonin, and dopamine. While its exact antiemetic mechanism is not fully defined, it is believed to help modulate neurotransmitter activity involved in the nausea pathway, potentially reducing the sensation of nausea.
Pregnancy: Pregnancy Category A (US FDA) for the specific combination when used as directed for NVP. Extensive data from cohort studies show no increased risk of major malformations. Considered first-line for NVP. However, use during pregnancy should be under medical supervision, and the benefit should outweigh any potential risk, especially in the first trimester. Indian context: Widely prescribed by obstetricians.
Driving: STRONGLY NOT ADVISED. Doxylamine causes significant drowsiness and impairs cognitive and motor functions. Patients must not drive or operate heavy machinery for at least 6-8 hours after a dose, and until their individual response is known.
| Alcohol | Potentiates CNS depression (sedation, dizziness, impaired coordination). | Major |
| Other CNS Depressants (Benzodiazepines, Opioids, Barbiturates, Sedating Antidepressants) | Additive CNS depression. | Major |
| Anticholinergic drugs (Atropine, TCAs, Antipsychotics like clozapine) | Additive anticholinergic side effects (dry mouth, constipation, urinary retention, confusion). | Moderate |
| Monoamine Oxidase Inhibitors (MAOIs) e.g., Phenelzine | Can intensify anticholinergic effects and cause hypertensive crisis. Contraindicated. | Major |
| Levodopa | Pyridoxine in high doses (>5mg) can accelerate peripheral metabolism of levodopa, reducing its efficacy in Parkinson's disease. The 10mg dose may have this effect. | Moderate |